ESMO: Abemaciclib Reduces Risk of Invasive Breast Cancer
Combination with endocrine therapy benefits high-risk patients Women with high-risk breast cancer...
Read More
Oncology / Hematology Newsletter
ESMO: Is KRAS Finally ’Druggable’?
Sotorasib results promising in phase 1 trial Results of a 129-patient phase I trial of sotorasib,...
Read More
ESMO: PROfound Final Analysis Confirms Olaparib Benefit in Tumors with BRCA1, BRCA2, or ATM Alterations
Longer overall survival for castration-resistant metastatic prostate ca In men whose...
Read More
A Welcome Guideline for Managing Newly Diagnosed AML in Older Adults
Acute myeloid leukemia (AML) generally develops in patients who fall into the “baby boomer”...
Read More
Another Coffee Perk—Prolonged Survival in Metastatic Colorectal Cancer?
Antioxidants in coffee may block cancer progression Coffee packed an unexpected “perk”...
Read More
TRITON2 Safety and Efficacy Findings Confirm PARP Benefit in mCRPC
Greater PSA response seen in BRCA2 alterations The poly (ADP-ribose) polymerase (PARP) inhibitor...
Read MoreBevacizumab and Platinum-Based Combinations for Recurrent Ovarian Cancer
Bevacizumab is a medication used to treat a wide range of cancers. Bevacizumab, along with carboplatin-paclitaxel, carboplatin–gemcitabine, or carboplatin–pegylated liposomal doxorubicin, is used as a state-of-the-art therapy...
Read More
Peritumoral Radiomics Promising in Esophageal Cancer
Data extraction from CT images may predict treatment response A closer and more sophisticated...
Read More
Adjuvant Therapy After Neoadjuvant FOLFIRINOX Prolonged Survival in Node+ Pancreatic Ca
The regimen did not affect survival in node negative patients Adjuvant chemotherapy prolonged...
Read More